NYSE$PRA
ProAssurance Corporation · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
ProAssurance reported net income of $15.5 million and operating income of $11.5 million for Q2 2024.
ProAssurance reported net income of $15.5 million, or $0.30 per diluted share, and operating income of $11.5 million, or $0.23 per diluted share, for the three months ended June 30, 2024. The results reflected strong net investment income and an improved net loss ratio in the Specialty P&C segment.
- Insurance underwriting results, including 9% renewal pricing increases in Medical Professional Liability (MPL) business, illustrate management’s ongoing actions to achieve sustained profitability
- Net investment income increased 16% as ProAssurance takes advantage of the higher interest rate environment as its portfolio matures
- Earnings benefited from strong returns from limited partnership investments
- Book value per share was $22.15 at June 30, 2024, while non-GAAP adjusted book value per share was $26.18
Headline financials
Revenue & EPS history
ProAssurance · Revenue · Quarterly
$290M
Revenue by segment
ProAssurance · $272M total across 4 segments · Q4 2024
- Specialty P&C$187M—68.7%
- Workers' Compensation Insurance$43.3M—15.9%
- Corporate$29.5M—10.9%
- Segregated Portfolio Cell Reinsurance$12.4M—4.5%
Forward guidance
ProAssurance is focused on disciplined underwriting and managing claims in a challenging loss environment. They are ahead of many in achieving rate levels in medical professional liability that outpace severity trends and are confident that these cyclical lines will respond to their focused efforts.
Tailwinds
- Strong net investment income
- Improved net loss ratio in Specialty P&C segment
- Renewal pricing increases of 9% in Medical Professional Liability
- Cumulative +65% premium change implemented since 2018
- Retention for the Specialty P&C segment remained a solid 84%
Headwinds
- Current market conditions are a headwind
- Prudent to shrink in some markets
- Net loss ratio in Specialty P&C segment not yet satisfactory
- Underwriting appetite remains constrained in Workers’ Compensation
- Higher loss trends related to rising medical costs per claim in Workers’ Compensation
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.4%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-0.7%
Avg return
30 days after
56%
38 / 68 earnings
Positive
+18.1%
Q2 2024
Best reaction
-22.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +0.2% | -0.5% | |
| Q4 2025 | +0.4% | +0.6% | +1.3% | |
| Q3 2025 | +0.2% | +0.3% | -0.4% | |
| Q1 2025 | -0.2% | +0.2% | +0.8% | |
| Q4 2024 | +14.3% | +10.8% | +65.5% | |
| Q3 2024 | +3.0% | +3.7% | +2.5% | |
| Q2 2024 | +18.1% | +15.5% | +14.6% | |
| Q1 2024 | +9.6% | +6.9% | +0.7% | |
| Q4 2023 | -4.7% | +0.2% | -0.8% | |
| Q3 2023 | -22.1% | -27.6% | -27.7% | |
| Q2 2023 | +8.2% | +8.2% | +3.7% | |
| Q1 2023 | -21.5% | -21.3% | -22.5% | |
| Q4 2022 | +4.7% | +3.7% | -5.9% | |
| Q3 2022 | -12.7% | -11.2% | -14.4% | |
| Q2 2022 | +6.1% | +6.7% | -4.3% | |
| Q1 2022 | -12.7% | -15.0% | -8.0% | |
| Q4 2021 | +1.1% | -0.9% | +3.4% | |
| Q3 2021 | -0.9% | -2.0% | -6.3% | |
| Q2 2021 | +5.4% | +17.5% | +23.7% | |
| Q1 2021 | +1.1% | -3.1% | -6.8% | |
| Q4 2020 | +5.0% | +5.6% | +13.7% | |
| Q3 2020 | -10.2% | +2.0% | +8.6% | |
| Q2 2020 | -2.1% | -5.1% | -12.2% | |
| Q1 2020 | -18.0% | -22.1% | -17.0% | |
| Q4 2019 | -0.2% | -5.4% | -22.7% | |
| Q3 2019 | +1.4% | -1.6% | -5.3% | |
| Q2 2019 | -0.6% | +1.6% | +3.7% | |
| Q1 2019 | -0.9% | +4.2% | +6.7% | |
| Q4 2018 | -3.7% | -9.3% | -22.3% | |
| Q3 2018 | +4.2% | -0.4% | -4.9% | |
| Q2 2018 | +5.5% | +6.8% | +16.1% | |
| Q1 2018 | -13.5% | -12.7% | -17.2% | |
| Q4 2017 | -6.9% | -5.4% | -7.5% | |
| Q3 2017 | +6.1% | +5.5% | +7.7% | |
| Q2 2017 | -5.0% | -6.0% | -10.7% | |
| Q1 2017 | +1.1% | -2.4% | -1.0% | |
| Q4 2016 | +8.9% | +4.9% | +4.0% | |
| Q3 2016 | -2.5% | -1.6% | +10.6% | |
| Q2 2016 | +2.4% | +5.4% | +5.7% | |
| Q1 2016 | +1.1% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | -0.9% | — | — | |
| Q2 2015 | +0.1% | — | — | |
| Q1 2015 | -3.5% | — | — | |
| Q4 2014 | +0.1% | — | — | |
| Q3 2014 | -4.9% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | -0.6% | — | — | |
| Q4 2013 | -2.2% | — | — | |
| Q3 2013 | +2.7% | — | — | |
| Q2 2013 | -6.3% | — | — | |
| Q1 2013 | +0.1% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2012 | -1.9% | — | — | |
| Q2 2012 | +0.9% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2011 | +5.7% | — | — | |
| Q4 2010 | +5.7% | — | — | |
| Q3 2011 | +2.0% | — | — | |
| Q2 2011 | +1.8% | — | — | |
| Q1 2010 | +0.4% | — | — | |
| Q1 2011 | +0.6% | — | — | |
| Q4 2008 | +8.2% | — | — | |
| Q3 2009 | +4.2% | — | — | |
| Q3 2010 | +4.2% | — | — | |
| Q2 2010 | -3.5% | — | — | |
| Q2 2009 | -3.5% | — | — | |
| Q4 2009 | -3.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro